As seen in the press release on March 14, 2016
, CordenPharma is pleased to announce the completion and approval of expanded Development Capabilities (CTD2) for mid-scale (up to 20 kg) contained capacity of highly potent and oncology oral dosage forms
in its CordenPharma Plankstadt
(DE) manufacturing facility. This new and expanded capability provides customers a complete offering in the contained manufacturing of oral dosage from grams to 150 Kg.